Security key
74275C403
Processa Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (PCSA)
CUSIP: 74275C403
Q1 2026 13F Holders as of 31 Mar 2026
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 2,351,108
- Total 13F shares
- 177,706
- Share change
- +62,532
- Total reported value
- $448,464
- Price per share
- $2.52
- Number of holders
- 10
- Value change
- +$140,839
- Number of buys
- 4
- Number of sells
- 5
Report period
Q1 2026
Institutions
10
Top holders
10
PCSA full security history
Previous quarter: Q4 2025
Processa Pharmaceuticals, Inc. SEC filings
Processa Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 74275C403
Recent filing periods:
Top shareholders of PCSA - Processa Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Chiliz Group Ltd. |
13D/G
|
HX Entertainment Ltd |
13%
|
305,644
|
$959,722 | $0 | 13 Feb 2026 | |
| INTRACOASTAL CAPITAL, LLC |
13D/G
|
Mitchell P. Kopin |
8.1%
|
200,000
|
$644,000 | $0 | 31 Dec 2025 | |
| CVI Investments, Inc. |
13D/G
|
— |
7%
|
200,000
|
$24,000 | -$576,000 | 31 Mar 2026 | |
| ARMISTICE CAPITAL, LLC |
13D/G
|
— |
5%
|
2,644,376
|
$608,206 | +$475,127 | 30 Jun 2025 | |
| 3i, LP |
13D/G
|
— |
4.9%
|
1,681,944
|
$504,583 | $0 | 17 Jun 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
1.3%
|
30,190
|
$86,947 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
1%
|
23,586
|
$67,928 | — | 31 Dec 2025 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.84%
|
19,691
|
$56,000 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.65%
|
15,323
|
$44,130 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.54%
|
12,640
|
$36,403 | — | 31 Dec 2025 | |
| Stonepine Capital Management, LLC |
13F
|
Company |
0.52%
|
12,323
|
$35,490 | — | 31 Dec 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.06%
|
1,390
|
$4,003 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
18
|
$52 | — | 31 Dec 2025 | |
| JONES FINANCIAL COMPANIES LLLP |
13F
|
Company |
0%
|
7
|
$20 | — | 31 Dec 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
6
|
$17 | — | 31 Dec 2025 | |
| James H. Stanker |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
36,029
mixed-class rows
|
$61,609 | — | 05 Apr 2024 | |
| Robert Michael Floyd |
3/4/5
|
Chief Operating Officer |
—
class O/S missing
|
172,061
|
$51,618 | — | 09 Feb 2023 | |
| Virgil Thompson |
3/4/5
|
Director |
—
mixed-class rows
|
241,907
mixed-class rows
|
$42,163 | — | 27 Jun 2023 | |
| Yorke Justin W. |
3/4/5
|
Director |
—
mixed-class rows
|
660,074
mixed-class rows
|
$11,248 | — | 01 Oct 2025 | |
| Khoso Baluch |
3/4/5
|
Director |
—
mixed-class rows
|
608,830
mixed-class rows
|
$5,893 | +$5,752 | 31 Mar 2026 | |
| Geraldine Pannu |
3/4/5
|
Director |
—
mixed-class rows
|
608,693
mixed-class rows
|
$5,546 | +$5,253 | 31 Mar 2026 | |
| James R. Neal |
3/4/5
|
Director |
—
mixed-class rows
|
607,323
mixed-class rows
|
$2,073 | +$2,000 | 31 Mar 2026 | |
| Khalid Islam |
3/4/5
|
Director |
—
class O/S missing
|
18,208
|
— | — | 31 Mar 2022 |
Institutional Holders of Processa Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (PCSA) as of Q1 2026
As of 31 Mar 2026,
Processa Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (PCSA) was held by
10 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
177,706 shares.
The largest 10 holders included
Connective Capital Management, LLC, Stonepine Capital Management, LLC, GEODE CAPITAL MANAGEMENT, LLC, VANGUARD CAPITAL MANAGEMENT LLC, VANGUARD FIDUCIARY TRUST CO, UBS Group AG, Tower Research Capital LLC (TRC), CITIGROUP INC, JONES FINANCIAL COMPANIES LLLP, and WELLS FARGO & COMPANY/MN.
This page lists
10
institutional shareholders reporting positions in this security
for the Q1 2026 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
10
Q1 2026 holders
10
Holder diff
0
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2026 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.